Actively Recruiting
Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below
Led by International Peace Maternity and Child Health Hospital · Updated on 2026-05-01
29
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
CONDITIONS
Official Title
Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Gestational age C= 28 weeks + 6 days
- Admission within 24 hours after birth
- Infants suspected of bronchopulmonary dysplasia based on respiratory symptoms such as rapid breathing and cyanosis requiring respiratory support
- Chest X-ray findings showing increased bilateral lung markings or ground-glass opacities with other causes like infection or heart disease ruled out
- Normal full-term newborns without history of severe lung diseases, birth asphyxia, hypoxic-ischemic encephalopathy, or other conditions affecting respiratory or nervous system development
You will not qualify if you...
- Major congenital anomalies such as congenital heart disease, craniocerebral deformity, respiratory structural abnormalities, or hereditary metabolic diseases
- Chromosomal defects including trisomy 13, 18, or 21
- Severe intracranial hemorrhage
- Multiple organ failure
- Severe lung infections
- Any other condition deemed unsuitable by the investigator for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
International Peace Maternity and Child Health Hospital
Shanghai, China
Actively Recruiting
Research Team
F
Fu Xuemei
CONTACT
L
Li Dan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here